Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company engaged in the discovery and development of novel allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer. Leveraging advanced immunotherapy techniques, Adicet Bio is pioneering the use of gamma delta T cells engineered with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to create 'off-the-shelf' therapies aimed at providing durable and effective treatments for patients.
Core Products and Pipeline:
- ADI-001: A first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, currently in a Phase 1 clinical trial for relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and autoimmune diseases such as lupus nephritis.
- ADI-270: An armored gamma delta CAR T cell product candidate targeting CD70, in preclinical development for renal cell carcinoma and other CD70+ solid and hematological malignancies.
Recent Achievements and Collaborations:
- FDA clearance of the Investigational New Drug (IND) application for ADI-001 in lupus nephritis and initiation of Phase 1 clinical trial expected in 2Q 2024.
- Strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics.
- Successful Series A financing round, raising $51 million led by Orbimed Partners, Orbimed Israel, and Novartis Ventures.
- Inducement awards granted to new employees as material inducements for employment, signifying ongoing growth and talent acquisition within the company.
- Presentation of promising preclinical data on ADI-270 at major scientific annual meetings, indicating robust anti-tumor activity and potential clinical benefits.
Financial Overview: Adicet Bio maintains a strong cash position with $247.6 million in cash and cash equivalents as of March 31, 2024, providing sufficient funding to support operations into the second half of 2026. The company continues to strategically invest in research and development, as well as in expanding its organizational capabilities.
Adicet Bio is at the forefront of innovation in the biotechnology space, striving to bring transformative therapies to patients with unmet medical needs. For more information, please visit Adicet Bio's official website.
Adicet Bio announced promising results from its Phase 1 study of ADI-001, targeting relapsed or refractory B-cell Non-Hodgkin's lymphoma. As of July 15, 2022, the therapy showed a 78% overall response rate and a 100% complete response rate in patients with prior CAR T therapy. No severe adverse events were reported, indicating a favorable safety profile. Adicet plans to present further data at the ASH Annual Meeting on December 10, 2022, and a webcast to discuss recent findings is scheduled for December 11, 2022.
Adicet Bio (NASDAQ: ACET) will have its CEO Chen Schor present at the Jefferies London Healthcare Conference from November 15-17, 2022. The presentation is scheduled for November 15 at 7:25 a.m. GMT. Interested parties can access the live audio webcast on Adicet Bio’s website, and an archived replay will be available for 30 days post-event.
Adicet is focused on developing allogeneic gamma delta T cell therapies for cancer, aiming to enhance anti-tumor immune response.
Adicet Bio, Inc. (NASDAQ: ACET) announced the granting of inducement awards on October 31, 2022, to 12 new hires under its 2022 Inducement Plan. The awards include non-qualified stock options to purchase 251,600 shares of common stock at an exercise price of $16.49 per share. Vesting will occur over four years, with one-fourth vesting after one year and the remainder in thirty-six equal monthly installments, contingent on continued employment. The inducement plan was approved by an independent board committee.
Adicet Bio (NASDAQ: ACET) will host an R&D webcast on November 10, 2022, at 9:00 AM EST, providing a pipeline overview. The company will showcase four preclinical abstract presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting on November 8-12, 2022, in Boston, MA. Topics include novel immune therapies targeting prostate cancer and CD70+ cancers. The abstracts will be available in the Journal for ImmunoTherapy of Cancer on November 7, 2022.
Adicet Bio, Inc. (NASDAQ: ACET) announced the grant of inducement stock options to new hires as part of its 2022 Inducement Plan on September 30, 2022. The awards, totaling 25,600 non-qualified stock options, offer an exercise price of $14.22 per share, the closing price on the grant date. These options will vest over four years, contingent upon continued employment. The plan was adopted in January 2022 and authorized by an independent compensation committee, aligning with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology firm specializing in allogeneic gamma delta CAR T cell therapies for cancer, announced participation in two upcoming investor conferences. The H.C. Wainwright 24th Annual Global Investment Conference will occur from September 12-14, 2022, with an on-demand presentation by Chen Schor, CEO, available from 7:00 A.M. ET on September 12. Additionally, a corporate overview will be presented at the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 8:00 A.M. ET. Live webcasts will be accessible on the company’s website.
Adicet Bio, Inc. (NASDAQ: ACET), a biotech company focused on cancer therapies, announced on August 31, 2022, the granting of inducement awards to five new employees as part of its 2022 Inducement Plan. The awards include non-qualified stock options for a total of 114,200 shares, priced at $14.16 each, the closing price on the grant date. These options will vest over four years, contingent upon continued employment. This plan aligns with Nasdaq regulations and aims to enhance employee retention and attract talent.
Adicet Bio reported second quarter results for 2022, highlighting significant clinical advancements for ADI-001, which achieved a 75% complete response rate in patients with relapsed aggressive NHL. The FDA granted Fast Track Designation for this investigational therapy. Financially, the company holds $304.3 million in cash as of June 30, 2022, following a successful at-the-market share offering generating $45 million. Despite a net loss of $22.5 million for the quarter, the company is well-capitalized to support operations through the first half of 2025.
Adicet Bio (NASDAQ: ACET), a clinical-stage biotechnology firm focused on allogeneic gamma delta CAR T cell therapies for cancer, announces management's participation in three investor conferences in August 2022. CEO Chen Schor will engage in a fireside chat at the BTIG Biotech Conference on August 8, participate in a virtual panel at the Wedbush Pacgrow Healthcare Conference on August 10, and present a corporate overview at the Canaccord Genuity Annual Growth Conference on August 11. Live webcasts will be accessible on the company’s investor website.
Adicet Bio, a clinical-stage biotechnology company, announced the granting of inducement awards on July 29, 2022, to seven new employees as part of its 2022 Inducement Plan. These awards consist of non-qualified stock options for a total of 87,000 shares at an exercise price of $16.89 each, corresponding to the stock's closing price on the grant date. The options will vest over four years, with one-fourth vesting on the one-year anniversary of the employees' start dates. This action is a strategic move to enhance employment incentives and attract talent in line with Nasdaq rules.
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
What is Adicet Bio, Inc.?
What are the key products in Adicet Bio's pipeline?
What recent achievements has Adicet Bio made?
How is Adicet Bio financially positioned?
What strategic collaborations has Adicet Bio entered into?
What is the focus of Adicet Bio's research and development?
What are ADI-001 and ADI-270?
What makes Adicet Bio's approach unique?
What is the significance of the FDA's fast track designation for ADI-001?
Where can I find more information about Adicet Bio?
